Focal Adhesion Proteins as Non-Invasive Podocyte Damage Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for kidney podocyte pathologies, such as focal segmental glomerulosclerosis (FSGS) and minimal change disease, are invasive and lack specific biomarkers, making it difficult to identify patients and differentiate between similar nephrotic syndromes, leading to ineffective treatment evaluation and potential kidney failure.
Innovation Solution
A system and method using a test kit to analyze plasma or urine for focal adhesion complex proteins (Integrin, Talin, Filamin, Vinculin, and associated antibodies) to identify podocyte damage, allowing for non-invasive diagnosis and prognosis of FSGS and other nephropathies, guiding immunosuppressive therapy, and monitoring treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive biopsy procedures are used to diagnose podocyte pathologies, then diagnostic accuracy is improved, but patient discomfort and procedural complexity increase
Solution Approach 1:
The invention extracts and measures focal adhesion complex proteins (integrin, talin, filamin, vinculin) from easily obtainable bodily fluids such as urine or plasma. By taking out the diagnostic function from invasive tissue biopsy and relocating it to non-invasive fluid sampling, the method maintains diagnostic accuracy while eliminating patient discomfort associated with kidney biopsies
Solution Approach 2:
The invention uses focal adhesion complex proteins in urine or plasma as intermediary biomarkers that reflect podocyte damage. These proteins serve as mediators between the actual podocyte pathology and the diagnostic test, allowing indirect but accurate diagnosis through non-invasive fluid analysis rather than direct tissue examination
2Loss of information
If kidney biopsy is performed to differentiate between FSGS and MCD, then etiology identification is improved, but procedural cost and time consumption increase
Solution Approach 1:
The invention applies local quality by detecting specific focal adhesion complex proteins that are differentially expressed or present in different patterns for FSGS versus MCD. By measuring the presence, concentration, or modification state of specific proteins like integrin or talin in urine, the method provides localized molecular signatures that differentiate etiologies without requiring global tissue examination through biopsy
Solution Approach 2:
The invention performs preliminary diagnostic action by measuring focal adhesion complex proteins in urine or plasma before committing to invasive biopsy procedures. This preliminary test provides sufficient etiology identification in many cases, allowing clinicians to make treatment decisions without proceeding to time-consuming and expensive biopsy procedures
3Adaptability or versatility
If immunosuppressive therapy is initiated without specific diagnosis, then treatment coverage is improved, but treatment effectiveness decreases
Solution Approach 1:
The invention performs preliminary etiology identification by detecting focal adhesion complex proteins in urine or plasma before initiating immunosuppressive therapy. This preliminary diagnostic action allows clinicians to determine whether the patient has FSGS (which may respond to immunosuppression) or MCD (which typically does not), thereby avoiding ineffective treatment and improving overall treatment effectiveness while maintaining appropriate treatment coverage
Data Source
AI summary
A system and method for identifying and/or predicting damage or disease of a patient's kidney podocyte layer, wherein the system includes a test kit configured to analyze the plasma or urine of the patient; and identify the presence of focal adhesion complex proteins, or anti-bodies associated with the focal adhesion complex proteins, in the plasma or urine, wherein the focal adhesion complex proteins comprise Integrin, Talin, Filamin, Vinculin, or other focal adhesion complex proteins. Wherein the presence of the focal adhesion complex proteins indicates damage or disease to the patient's podocyte layer and the presence of the associated anti-bodies may be used to predict the likelihood of developing damage.